Topical issues of the clinical use of Candesartan as an angiotensin receptor blocker 
Maksimov M.L.^1, Dralova O.V.², Kurguzova D.O.<sup>2

1</sup> Kazan State Medical Academy - a branch of Russian Medical Academy of Сontinuous Professional Education 
² First Moscow State Medical University named after I.M. Sechenov

Arterial hypertension is one of the most important and modifiable risk factors for cardiovascular complications. Renin-angiotonezin-aldosterone system (RAAS) is extremely important for the regulation of many parameters of the cardiovascular system and kidney function, including maintenance of arterial pressure and water-salt metabolism. Also, RAAS plays a leading role in the formation of cardiovascular pathology and the development of hypertension, atherosclerosis, coronary heart disease, and chronic heart failure. Angiotensin (AT) II is very important for damaging the target organs, contributing to vasoconstriction, hypertrophy, fibrosis and remodeling of arterial vessels and myocardium, development of endothelial dysfunction, atherosclerosis and other disorders. Adverse effects of hyperactivated RAAS are realized through angiotensin II-stimulated AT1 receptors, which is expressed in the provocation of vasocontraction and inflammation, in hypertrophy and fibrosis of the heart muscle and blood vessels. Angiotensin receptor blockers selectively prevent the stimulation of AT1 receptors, which are associated with most of the negative effects of angiotensin II. Candesartan is a selective antagonist of angiotensin II type 1 receptors, successfully used in patients with arterial hypertension and chronic heart failure. The article reviews the results of the most significant domestic and international studies on the efficacy and safety of candesartan.

Key words: candesartan, Hyposart, angiotensin receptor blockers, angiotensin II receptor antagonists, sartans, efficacy, safety, generic, arterial hypertension, chronic heart failure, renin-angiotensin-aldosterone system.
For citation: Maksimov M.L., Dralova O.V., Kurguzova D.O. Topical issues of the clinical use of Candesartan as an angiotensin receptor blocker // RMJ. 2017. № 20. P. 1466–1470.